Alkermes plc. 4

EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised options for 5,000 Alkermes plc ordinary shares and sold 9,000 shares at $48.58, ending with 69,389 shares owned.

On 2026-08-03, Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, exercised two tranches of employee stock options to acquire a total of 5,000 ordinary shares (104 shares at $19.34 and 4,896 shares at $24.59) and subsequently sold 9,000 ordinary shares at $48.58 per share under a Rule 10b5-1 trading plan adopted on 2025-03-14. The option exercises were at zero cost to the issuer (standard option exercise pricing reflected separately in the derivative table) and the sales generated total proceeds of approximately $437,220, leaving Hopkinson with 69,389 ordinary shares directly owned after the transactions. The options exercised were fully vested pursuant to their terms, and the trades appear to be part of a pre-arranged liquidity and diversification strategy rather than an opportunistic open-market sale.

Filing Facts

CIK

1520262

Ticker

ALKS

Form

4

Source Type

fda

Accession

0001520262-26-000110

Alert Tier

6